What does a modified-Fibonacci dose-escalation actually correspond to?

BACKGROUND: In most phase I oncology trials, it is often stated that the dose increments follow a “modified-Fibonacci sequence”. This term, however, is vague. METHODS: To better characterize this sequence, we reviewed 81 phase I trials based on this concept. RESULTS: Out of 198 phase I oncology tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Penel, Nicolas, Kramar, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538691/
https://www.ncbi.nlm.nih.gov/pubmed/22824322
http://dx.doi.org/10.1186/1471-2288-12-103
Descripción
Sumario:BACKGROUND: In most phase I oncology trials, it is often stated that the dose increments follow a “modified-Fibonacci sequence”. This term, however, is vague. METHODS: To better characterize this sequence, we reviewed 81 phase I trials based on this concept. RESULTS: Out of 198 phase I oncology trials, 81 (41%) are based on modified-Fibonacci series. Actual incremental ratios varied in a large range from 0.80 to 2.08. The median of actual increments was about 2.00, 1.50, 1.33, 1.33, 1.33, 1.33, 1.30, 1.35…. The “modified Fibonacci-sequence” gathers heterogeneous variation of the genuine sequence, which does not tend to a constant number at higher dose-levels. CONCLUSION: This confusing term should be avoided.

Ejemplares similares